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Abstract
Background Beta-interferon (IFN-β) and glatiramer acetate (GA) have been evaluated in people with clinically isolated syn-
drome (CIS) with the aim to delay a second clinical attack and a diagnosis of clinically definite multiple sclerosis (CDMS). 
We systematically reviewed trials evaluating the short- and long-term clinical effectiveness of these drugs in CIS.
Methods We searched multiple electronic databases. We selected randomised controlled studies (RCTs) conducted in CIS 
patients and where the interventions were IFN-β and GA. Main outcomes were time to CDMS, and discontinuation due 
to adverse events (AE). We compared interventions using random-effect network meta-analyses (NMA). We also reported 
outcomes from long-term open-label extension (OLE) studies.
Results We identified five primary studies. Four had open-label extensions following double-blind periods comparing out-
comes between early vs delayed DMT. Short-term clinical results (double-blind period) showed that all drugs delayed CDMS 
compared to placebo. Indirect comparisons did not suggest superiority of any one active drug over another. We could not 
undertake a NMA for discontinuation due to AE. Long-term clinical results (OLE studies) showed that the risk of develop-
ing CDMS was consistently reduced across studies after early DMT treatment compared to delayed DMT (HR = 0.64, 95% 
CI 0.55, 0.74). No data supported the benefit of DMTs in reducing the time to, and magnitude of, disability progression.
Conclusions Meta-analyses confirmed that IFN-β and GA delay time to CDMS compared to placebo. In the absence of 
evidence that early DMTs can reduce disability progression, future research is needed to better identify patients most likely 
to benefit from long-term DMTs.
Keywords Multiple sclerosis · Clinically isolated syndrome · Beta-interferon · Glatiramer acetate · Systematic review
Introduction
Relapsing–remitting multiple sclerosis (RRMS) often origi-
nates from a single demyelinating event, known as clinically 
isolated syndrome (CIS) [1]. CIS events are isolated events 
of symptomatic neurological disturbance lasting more than 
24 h, which indicate the first clinical demyelination of the 
central nervous system [2]. Clinical syndromes are usually 
mono-focal but occasionally multi-focal in nature. Based on 
the previous diagnostic classifications of multiple sclerosis 
(MS) [3, 4], people with CIS could be categorised as high 
risk of developing MS but without being formally diagnosed 
with MS. With the revisions in the magnetic resonance 
imaging (MRI) component of the 2010 McDonald criteria 
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[5], it is now possible to be diagnosed with MS after CIS if 
repeated MRI imaging shows multiple demyelinating lesions 
of the central nervous system developing over time, which 
has lead to an increased rate of MS diagnosis in patients 
with CIS [6].
Disease-modifying therapies (DMTs) are commonly 
prescribed for people diagnosed as having MS. Most ran-
domised controlled trials (RCTs) conducted in RRMS have 
sought to include patients with at least two acute clinical 
exacerbations in the prior years. First-generation DMTs, 
such as beta-interferon (IFN-β) and glatiramer acetate (GA), 
have also been evaluated in people with CIS with the aim of 
delaying a second clinical attack leading to the diagnosis of 
clinically definite MS (CDMS).
In 2008, a systematic review assessed these two types 
of DMTs in this specific population [7] but newer evidence 
has become available since then. Moreover, this systematic 
review assessed the effectiveness of DMTs over a short fol-
low-up duration (2–3 years), which is insufficient to evaluate 
the long-term clinical effectiveness of DMTs over placebo. 
This is of particular importance when accounting for the 
frequent occurrence of adverse events with first-generation 
DMTs. For example, flu-like symptoms occur in 40–75% of 
patients with IFN-β, and injection-site reactions and pain 
are reported by at least one-third of patients with IFN-β or 
GA [8]. These adverse events can affect the quality of life 
of patients who may otherwise have only limited disability 
at this very early disease stage. While an RCT comparing 
an early to a pre-planned delayed initiation of DMTs would 
be the best study design to investigate the optimal treatment 
sequence after CIS, the long-term benefit of early DMTs can 
be partially assessed from the open-label extension phases of 
studies which originally compared DMTs to placebo. Thus, 
in this systematic review and network meta-analysis (NMA), 
we examined the short- and long-term clinical effectiveness 
of first-generation DMTs in people with CIS.
Methods
Search method
The current work follows a systematic review (PROSPERO 
identifier: CRD42016043278) that was undertaken as part 
of a larger project assessing the clinical and cost effec-
tiveness of IFN-β and GA acetate for MS within the UK 
[8]. The following electronic databases were searched for 
RCTs in CIS in February 2016: Cochrane Multiple Scle-
rosis and Rare Diseases of the CNS group specialised reg-
ister; MEDLINE (Ovid); MEDLINE In-Process and Other 
Non-Indexed Citations (Ovid); Embase (Ovid); Cochrane 
Library (Wiley), including Cochrane Database of System-
atic Reviews, Cochrane Central Register of Controlled Trials 
(CENTRAL), DARE, NHS EED, and HTA databases); 
Science Citation Index and Conference Proceedings—Sci-
ence (Web of Science); UKCRN Portfolio Database; WHO 
ICTRP; Current Controlled Trials; ClinicalTrials.gov. No 
date restriction was applied. The included and excluded 
study lists from previous relevant Cochrane systematic 
reviews were also checked [9–11]. Additionally, any CIS 
RCTs identified during the broader MS systematic review 
were also considered for inclusion. These additional searches 
are described in the report of this larger project [8] (Online 
resource 1). During our original work, we also identified 
long-term follow-up studies of immediate versus delayed 
treatment at title/abstract level, but excluded them at full-text 
review. For the purpose of the current review, we retrieved 
these records from our initial list of excluded references and 
undertook targeted searches using more than one source to 
find other potential subsequent reports from the original CIS 
studies.
Selection criteria
Our original systematic review included RCTs conducted in 
people with RRMS, SPMS, or CIS, evaluating all forms of 
beta-interferon (IFN β-1a; pegylated IFN β-1a; IFN β-1b) 
and GA compared against each other or placebo/best sup-
portive care, and where clinical outcomes were reported 
such as relapse rates, progression to multiple sclerosis, or 
disability progression as measured by the Expanded Disabil-
ity Status Scale (EDSS). We consider here a subset of stud-
ies reporting RCTs conducted in people with a single clinical 
attack diagnosed as having CIS and where the interventions 
were used at the authorised dose regimen (IFN β-1b 250 µg 
subcutaneously (SC) every other day for  Betaferon® (Bayer, 
Leverkusen, Germany) and  Extavia® (Novartis, Basel, Swit-
zerland); IFN β-1a 30 µg intramuscularly (IM) once weekly 
for  Avonex® (Biogen Idec Ltd, Cambridge, MA, USA); GA 
20 mg SC daily for  Copaxone® (Teva Pharmaceutical Indus-
tries, Petah Tikva, Israel); IFN β-1a 44 µg SC three times 
weekly for  Rebif® (Merck, Darmstadt, Germany)).
Our main outcomes of interest were: (1) time to CDMS 
using Poser criteria [12] and involving a second relapse or 
neurological deterioration, measured using hazard ratios 
(HR); we also undertook a sensitivity analysis examining 
time to ‘McDonald MS’ instead of time to CDMS, in which 
MRI findings could be used with clinical findings to arrive at 
a diagnosis; (2) discontinuation due to AE, measured using 
risk ratios (RR). Although these were not included in our 
original systematic review, we also included long-term open-
label extension studies following the double-blind period of 
RCTs that had enrolled patients with CIS. Open-label exten-
sion studies were defined as studies that compared all those 
randomised to active treatment who continued on treatment 
in extension phase (early DMT) versus all those randomised 
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initially to placebo who then crossed over to active treatment 
in extension phase (delayed DMT). We used these studies to 
explore the impact of DMTs on disability progression, which 
was measured using the Expanded Disability Status Scale 
(EDSS). We also examined long-term annualised relapse 
rates (ARR) from open-label studies.
Study selection process
In our initial work, we first examined relevant past system-
atic reviews from the Cochrane MS group [7, 10, 11] for 
studies meeting the inclusion criteria. For updated and new 
searches, we collected all retrieved records in a specialised 
database and duplicate records were identified and removed. 
Subsequently, two reviewers applied the inclusion/exclusion 
criteria and screened all identified bibliographic records for 
title/abstract and then for full text. Any disagreements were 
resolved through discussion consensus or by recourse to a 
third-party reviewer.
Data extraction, quality assessment, and synthesis
Data extraction was performed by two reviewers and was 
cross-checked. Any disagreement was resolved through dis-
cussion or recourse to a third reviewer. We undertook the 
quality assessment of included studies using the Cochrane 
risk of Bias tool for randomised-controlled trials [13]. The 
quality assessment was cross-checked within the reviewer 
team. Any disagreements were resolved as in earlier stages. 
The included papers were organised in text and tables. The 
summary tables tabulated characteristics and results for 
included primary studies. Tables for primary studies present 
summary data on participants, interventions, and outcomes.
For RCTs reported up to the end of double-blind periods, 
we performed a conventional pairwise meta-analysis using a 
method-of-moment random effects model (inverse-variance 
weighted) to directly compare each pair of interventions for 
which direct evidence exists, and to compare included DMTs 
as a class against placebo. We examined these pairwise meta-
analyses for heterogeneity, measured as Cochran’s Q and  I2. 
We then estimated random effects network meta-analyses in 
the frequentist framework, using package network in Stata 
v.14. For each outcome of interest, a network diagram of pair-
wise direct comparisons between multiple treatments was cre-
ated. Tests for inconsistency were inapplicable because the 
network was star shaped. The summary estimates (with 95% 
CIs) for all pair-wise comparisons were provided in a league 
table [14]. We aimed to determine the rankings of all treat-
ments (e.g. based on the relative probability of an intervention 
being superior) with respect to effectiveness and safety out-
comes in reference to placebo/standard care and we used the 
surface under the cumulative ranking curve (SUCRA) [14].
For open-label extension studies, we calculated a pooled 
estimate of the effect of early DMT, including all DMTs as 
a class, compared to delayed DMT on time to CDMS (effect 
again measured as HR) through a method-of-moments ran-
dom effects meta-analysis. When HR were reported at differ-
ent follow-up durations, we used the most mature data, i.e. 
those with the longest follow-up. In these studies, the out-
comes were only reported for patients originally randomised 
to active treatment or placebo, who entered extension phase. 
Our exploratory work measuring the impact of early DMT 
on disability progression and examining long-term ARR was 
summarised narratively.
Results
Study identification and characteristics
Our original searches identified 6420 records. Of these, 6146 
were excluded based on title and/or abstract, leaving 274 to 
be examined at full-text (Fig. 1).
Among these, 14 records [15–28] (including two addi-
tional ones from our later targeted search) met our inclusion 
criteria and corresponded to five trials: BENEFIT compar-
ing IFN β-1b 250 µg SC every other day to placebo [15]; 
CHAMPS [16] and Pakdaman et al. [17] both evaluating 
IFN β-1a 30 µg IM once a week against placebo; PRECISE 
comparing the effect of GA 20 mg SC once daily to pla-
cebo [18]; and REFLEX comparing IFN β-1a 44 µg SC 
three times a week against placebo [19]. In these trials, all 
included patients had a single clinical event and also had evi-
dence of clinically silent lesions based on MRI. The double-
blind period in these trials was 2 years after randomisation in 
BENEFIT and REFLEX, and 3 years in PRECISE, Pakda-
man et al. [17], and CHAMPS (Table 1).
Nine of the 14 selected records were open-label exten-
sion studies of four of the five above-listed trials (Online 
resource 2): BENEFIT with long-term follow-up at 3, 5, 
8, and 11 years [20–23]; CHAMPS with results at 5 and 
10 years (CHAMPIONS study) [24, 25]; PRECISE with a 
prolonged follow-up at 5 years [27]; and REFLEX with a 
5-year follow-up (REFLEXION study) [26, 28]. We found 
no subsequent long-term follow-up for the Pakdaman et al. 
[17] RCT. In open-label extension studies, patients initially 
allocated to placebo were offered active treatment from 
the time of a second clinical attack or after the end of the 
double-blind period (delayed DMT group). Conversely, 
people initially allocated to active treatment were offered 
to continue on treatment during an extension study (early 
DMT group). Overall, the proportion of patients entering 
open-label extension studies ranged from 53 to 86% after 
completion of the double-blind phase with no significant 
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differences between the two groups (early or delayed DMTs) 
within each study (Online resource 2).
We judged there was a substantial proportion of studies 
with insufficient information to rate the risk of selection bias 
(60% of studies rated as unclear risk on random sequence 
generation and 40% of studies rated as unclear risk on allo-
cation concealment) (Online resource 3 and 4). Although 
studies were placebo controlled, we found that four of the 
five (80%) studies were at high risk of performance bias (due 
to loss of blinding of participant and personnel). This was 
because of the much increased rates of side effects such as 
injection-site reactions in patients allocated to active treat-
ment which led to high risk of participant unblinding.
Overall, we found no major issue of detection (blinding 
of outcome assessment) or reporting bias across studies. 
Only one study [17] was rated as at high risk at attrition 
bias (incomplete outcome data). Understandably, the open-
label extension studies were at much higher risk of attrition 
bias with a range of complete follow-up rates after entering 
the extension phase of 44–96%. Finally, all studies funded 
by drug manufacturers were designated as high risk of bias 
under the ‘other’ category.
Short‑ and long‑term clinical outcomes
Short-term clinical outcomes were informed by the results 
from the double-blind period of RCTs.
Time to CDMS: short‑term outcomes
Direct evidence from comparisons showed all drugs reduced 
the time to CDMS compared to placebo (Fig. 2). There was 
Fig. 1  PRISMA flowchart
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little heterogeneity (I2 = 0%, p = 0.72) for the IFN β-1a 
30 μg IM once a week vs. placebo comparison, which was 
the only one that included more than one study. Accounting 
for all DMT and considering a class effect for DMTs used 
in CIS, the pooled HR for time to CDMS was 0.51 (95% CI 
0.44, 0.61) with low heterogeneity (I2 = 0%, p = 0.98).
The set of studies reporting hazard ratios for time to 
CDMS formed a connected, star-shaped, network (Fig. 3). 
Our random-effect NMA showed similar results compared 
to pairwise comparisons for active vs placebo comparisons 
(Table 2). There was no evidence from indirect comparisons 
suggesting superiority of any one active drug over another. 
Rankings from the NMA suggested that IFN β-1a 44 μg SC 
thrice weekly was ranked best, followed by IFN β-1b 250 μg 
SC every other day, IFN β-1a 30 μg IM once a week and GA 
20 mg SC once daily while placebo was ranked last.
As a result of our sensitivity analysis, we found that 
effectiveness estimates were robust to the use of time to 
McDonald MS instead of time to CDMS [pooled HR for 
time to ‘McDonald MS’ 0.52 (95% CI 0.46, 0.60); I2 = 0%; 
p = 0.93].
Discontinuation due to AEs: short‑term outcomes
All but Pakdaman et al. [17] reported discontinuation due to 
AEs. However, the time point to assess this outcome was not 
consistent across the four studies (36 months in PRECISE 
Fig. 2  Pairwise meta-analyses, time to clinically definite MS (active drug vs placebo)
Fig. 3  Network of studies, time to clinically definite MS. ifn1a30: 
IFN β-1a 30 µg IM once a week; ifn1a44: IFN β-1a 44 µg SC three 
times weekly; ifn1b250: IFN β-1b 250 µg SC every other day; ga20: 
GA 20 mg SC once daily; plac: placebo
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and CHAMPS; 24 months in REFLEX and BENEFIT). 
Therefore, we chose not to undertake a NMA for discon-
tinuations due to AE. Estimates from published papers are 
presented in Table 3 and do not show clear trends across 
studies.
Time to CDMS: long‑term outcomes
Open-label extension studies informed the long-term clinical 
outcomes. Results presented below include data reported 
over both original and extension phases (Online resource 2).
At 5 years (3 years of open-label extension in REFLEX-
ION [26] and CHAMPIONS [25]), early IFN β-1a 30 µg IM 
once weekly led to a delayed time to CDMS compared to the 
late use of these agents. This was also observed at 10 years 
(open-label extension in CHAMPIONS [24]) for early IFN 
β-1a 30 µg IM once weekly. These findings were robust to 
the use of time to McDonald MS instead of time to CDMS. 
In CHAMPIONS [24, 25], ARR in patients with delayed 
DMT was doubled over the 5- and 10-year periods com-
pared to early DMT (0.31 vs 0.14, respectively; p = 0.03). 
At 10 years, 81% of patients had EDSS score ≤ 2.5 and only 
6% with EDSS ≥ 6.0, with no significant difference between 
early and delayed IFN β-1a 30 µg IM once weekly.
In BENEFIT, results from open-label extension follow-
up showed a reduced risk of developing CDMS with early 
IFN β-1b 250 µg SC every other day compared to delayed 
use of the same DMT for up to 9 years of additional follow-
up [20–23]. At 5 years (i.e. including 3 years of open-label 
extension), risk of EDSS progression in early DMT vs delayed 
DMT was 25 and 29%, respectively, annualised relapse rates 
were lower with early IFN β-1b 250 µg SC every other day 
(0.21 vs 0.27, respectively; p = 0.014) while EDSS scores 
were stable in both groups (− 0.03 compared to baseline with 
early DMT and + 0.07 compared to baseline with delayed 
DMT) [23]. At 8 years (6 years of open-label extension), over-
all ARR was reduced by 22.9% and relapse risk was reduced 
by 23.4% (HR 0.77, 95% CI 0.589–0.988; p = 0.048) with 
early DMT [20]. EDSS scores at the end of the 8-year period 
were on average 1.87 with early DMT (+ 0.38 change from 
baseline) and 1.56 with delayed DMT (+ 0.07 compared to 
baseline). At 11 years (9 years of open-label extension), over-
all ARR was lowered with early IFN β-1b vs delayed IFN β-1b 
(0.21 vs 0.26, respectively, p = 0.0018) while EDSS scores 
had minimal changes remaining low in both groups (mean of 
2.04 with early IFN β-1b, + 0.55 compared to baseline; mean 
of 2.22 with delayed IFN β-1b, + 0.72) [21].
With early GA, the time to CDMS was delayed by 41% 
(HR 0.59; 95% CI 0.44–0.80) compared to delayed GA 
at 5 years [27]. ARRs were 0.11 and 0.16, respectively 
(p = 0.0241). EDSS score changes over the 5-year period 
were minimal.
Table 2  Network meta-analysis: time to CDMS
Findings are expressed as HR (95% CI)
Drug SUCRA IFN β-1a 44 μg 
SC thrice 
weekly
IFN β-1b 250 μg 
SC every other 
day
IFN β-1a 30 μg IM 
weekly
Glatiramer 20 mg daily Placebo
IFN β-1a 44 μg SC thrice 
weekly
0.70 0.96 (0.56, 1.65) 0.93 (0.56, 1.55) 0.87 (0.51, 1.50) 0.48 (0.31, 0.74)
IFN β-1b 250 μg SC 
every other day
0.68 0.97 (0.63, 1.50) 0.91 (0.57, 1.45) 0.50 (0.36, 0.70)
IFN β-1a 30 μg IM 
weekly
0.62 0.94 (0.61, 1.45) 0.52 (0.39, 0.68)
Glatiramer 20 mg daily 0.5 0.55 (0.40, 0.76)
Placebo 0
Table 3  Discontinuation due to AEs in CIS studies
Study Comparison Follow-
up 
(months)
Treatment 
arm events
Treat-
ment 
group
Treatment 
events propor-
tion (%)
Placebo 
arm 
events
Placebo group Placebo events 
proportion (%)
PreCISe 2009 GA 20 mg daily vs. placebo 36 14 243 5.8 4 238 1.7
REFLEX 2012 IFN β-1a 44 μg SC thrice 
weekly vs. placebo
24 5 171 2.9 6 171 3.5
CHAMPS 2000 IFN β-1a 30 μg IM weekly 
vs. placebo
36 1 193 0.5 7 190 3.7
BENEFIT 2006 IFN β-1b 250 μg SC every 
other day vs. placebo
24 24 292 8.2 1 176 0.6
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Accounting for all DMTs, the pooled HR for time to 
CDMS was 0.64 (95% CI 0.55, 0.74) with low heterogene-
ity (I2 = 0%, p = 0.89) (Fig. 4) demonstrating the benefit of 
early vs delayed DMT.
Discussion
Meta-analyses confirmed that IFN-β and GA delayed the 
time to CDMS after CIS compared to placebo. No active 
drug showed superiority over another. Similar findings were 
observed in our sensitivity analysis using time to McDonald 
MS instead of time to CDMS. We were not able to compare 
drugs in relation to the risk of discontinuation due to AE.
Findings from open-label extension studies suggested a 
persistent long-term benefit in terms of time to CDMS for 
earlier treatment, despite the relatively short delay in treat-
ment initiation (2–3 years). However, these results should 
be treated with caution because of a high-risk of selection 
bias which may make delayed DMT appear worse than early 
DMT. The fact that patients initially allocated to placebo 
were offered active treatment from the time of a second 
clinical attack, and that the risk of developing CMDS was 
reduced with DMT compared to placebo over the double-
blind period means that those in placebo arms who had a 
second attack were more likely to get into extension phase. 
This would result in higher risk of MS in the delayed DMT 
group than in the early DMT group. Moreover, most of 
these studies had large losses to follow-up (14–47%), which 
gives the potential for attrition bias. This makes it difficult 
to be certain of the long-term benefit in delaying the time 
to CDMS.
The evidence showing the benefit of IFN-β and GA in 
delaying time to CDMS after CIS could underline the impor-
tance of initiating specific therapies in a timely manner fol-
lowing CIS. However, the decision about whether to start 
DMTs is more complex. Some patients with CIS will never 
have a second attack even off treatment. This is suggested 
by cohort studies reporting high proportions of CIS patients 
having no second attack despite not receiving DMTs, 55% 
after a mean follow-up of 5.8 years according to Brownlee 
et al. [29], or 27% at 10 years in the paper by Kerbrat et al. 
Fig. 4  Pooled estimate of time to CDMS (early vs delayed DMT)
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[30]. Also, some patients with CIS may only have a few 
minor non-disabling attacks. These patients with benign dis-
ease would not gain any/much benefit from treatment but 
would be exposed to unnecessary risk and/or experience 
frequent local or systemic adverse events which may reduce 
their quality of life.
For those who are at high risk of developing more severe 
MS, there may be some merit in delaying a second attack, 
but the key aim (from both a clinical and cost-effective per-
spective) would be to delay irreversible, progressive dis-
ability and there is no evidence at present that early treat-
ment after CIS does this. An analogous situation might be 
whether to use anticonvulsants after a single seizure, given 
that some patients will never have another seizure. This is 
generally not recommended, at least in the UK, because the 
evidence shows early treatment does not improve long-term 
outcome [31].
The main strength of our work is that we present an up-
to-date review on the clinical outcomes of first-generation 
DMTs, namely IFN-β and GA, used in people with CIS. 
For that purpose, we used a rigorous and comprehensive 
search to identify all existing primary studies. This is also 
the first review to include open-label extension studies, 
which provide a signal (albeit biased as previously dis-
cussed) of the longer term clinical effectiveness of DMTs 
in this population.
There were several limitations. We were interested in peo-
ple with CIS and we only included studies where patients 
had a single clinical attack. It is possible that some of these 
patients would now meet diagnostic criteria for MS based on 
new MRI criteria [5], which means that some of these would 
be considered eligible to begin DMTs. However, given that 
our main interest was to assess the evidence related to the 
clinical effectiveness of DMTs in people with a single clini-
cal event we feel this is a minor limitation. To the best of our 
knowledge, there is no RCT which evaluates the effective-
ness of DMTs in people with CIS using the new diagnostic 
criteria. A second limitation is the inconsistent reporting of 
safety outcomes, which led to an inability to compare DMTs 
on discontinuation due to AE. However, we believe that the 
safety profile of DMTs in CIS can be understood through the 
results observed in people with RRMS. Indeed, there is no a 
priori reason why the safety profile of IFN-β and GA would 
differ in people with CIS compared to those with RRMS 
because the drugs, strength and dose regimens are similar 
across both indications. In our work conducted in RRMS 
based on follow-up at 24 months, we found no evidence 
that one drug was more likely to lead to discontinuation 
than other, although confidence intervals for estimates from 
mixed treatment comparisons were wide. Therefore, we are 
fairly confident that these findings also apply in CIS patients.
Although we originally reviewed studies reporting long-
term open-label extensions of RCTs conducted in people 
with CIS, this work was conducted post hoc after the origi-
nal work for our initial systematic review. However, we con-
ducted additional searches for this analysis and are, there-
fore, reasonably confident that we retrieved all extension 
studies published as original articles and that no bias was 
introduced in this subsequent analysis. Finally, a potential 
limitation of our work, inherent to all systematic reviews, is 
publication bias since, for instance, some studies finding no 
impact of DMTs in people with CIS might have remained 
unpublished. There were too few studies to formally test 
for this.
In this review, we have focused on first-generation DMTs 
(IFN-β and GA) since these were all evaluated in CIS-spe-
cific RCTs. Oral teriflunomide, a newer generation DMT, 
has also been tested for patients with CIS in a RCT [32] that 
reported a benefit over placebo in delaying time to CDMS, 
yet with the same uncertainty on long-term clinical benefit.
At the European level, we are aware of the 2015 guide-
lines for prescribing disease-modifying treatments in MS 
[33]. Our findings agree with these guidelines, stating the 
benefits of use of the only two DMT types with a licensed 
indication in CIS in delaying CDMS, namely IFN-β and GA. 
The Association of British Neurologists (ABN) guidelines 
also emphasise the uncertainty around the effectiveness of 
these drugs over a long-term perspective.
In summary, IFN-β and GA reduce the short-term (up 
to 2–3 years) risk of a second clinical attack after CIS and 
so delay the diagnosis of CDMS. Open-label extension 
studies suggest a possible long-term effect of IFN-β and 
GA in delaying CDMS but there is less certainty because 
of the risk of bias of these studies. There is currently no 
evidence supporting the effectiveness of DMTs follow-
ing CIS in delaying irreversible or progressive disabil-
ity. Further research with RCTs is needed to specifically 
assess early vs delayed DMT after CIS to establish the 
long-term benefit/risk balance of DMTs and whether high-
risk patients who might benefit more from early treatment 
can be identified.
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